title: Serial extracellular matrix changes in neointimal lesions of human coronary artery after percutaneous transluminal coronary angioplasty: clinical significance of early tenascin-C expression.
abstract: It has become clear that deposition of extracellular matrix(ECM) proteins is a major cause of human restenosis after percutaneous coronary angioplasty (PTCA). To define the composition and organization of the involved ECM in human restenotic tissue, we morphologically and semiquantitatively analyzed specimens obtained by means of directional coronary atherectomy at various stages after PTCA with anti-fibronectin, tenascin-C, collagens I and III, and PG-M/versican antibodies. Tenascin-C deposition transiently increased within 1 month after PTCA, when smooth muscle cell migration and proliferation was active. Following the disappearance of tenascin-C, PG-M/versican accumulation increased and peaked between 1 month and 3 months when clinical restenosis was most actively progressing. At later stages, the PG-M/versican was replaced by a more mature ECM consisting of collagens I and III. The volume ratio of elastin remained at a low level throughout. Our results demonstrate that the matrix proteins of human restenotic lesions sequentially change after angioplasty and that tenascin-C could be a key molecule in the early stages.
authors.affiliation: Department of Pathology, Mie University School of Medicine, Tsu, Japan. imanaka@doc.medic.mie-u.ac.jp
authors.forename: K
authors.initials: K
authors.lastname: Imanaka-Yoshida
authors.forename: R
authors.initials: R
authors.lastname: Matsuura
authors.forename: N
authors.initials: N
authors.lastname: Isaka
authors.forename: T
authors.initials: T
authors.lastname: Nakano
authors.forename: T
authors.initials: T
authors.lastname: Sakakura
authors.forename: T
authors.initials: T
authors.lastname: Yoshida
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D011508:Chondroitin Sulfate Proteoglycans / Q000378:metabolism; D003094:Collagen / Q000378:metabolism; D003331:Coronary Vessels / Q000378:metabolism* / Q000473:pathology; D016326:Extracellular Matrix Proteins / Q000378:metabolism*; D005260:Female; D005353:Fibronectins / Q000378:metabolism; D006083:Graft Occlusion, Vascular / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D037181:Lectins, C-Type; D008297:Male; D008875:Middle Aged; D019063:Tenascin / Q000378:metabolism*; D017539:Tunica Intima / Q000378:metabolism* / Q000473:pathology; D053675:Versicans
chemical_list: D011508:Chondroitin Sulfate Proteoglycans; D016326:Extracellular Matrix Proteins; D005353:Fibronectins; D037181:Lectins, C-Type; D019063:Tenascin; C508322:VCAN protein, human; D053675:Versicans; D003094:Collagen